Multiple Myeloma Clinical Trials in Atlanta, Georgia

29 studies are recruiting for multiple myeloma in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Atlanta, Georgia

   Locations

   46 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Winship Cancer Institute, Emory University, Atlanta, Georgia

   Locations

   60 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

3. Collection of Tissue Samples for Cancer Research

   Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research …

   Stage

   Not phased

   Ages

   0 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   17 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT00900198 on ClinicalTrials.gov

4. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory University Hospital, Atlanta, Georgia

   Locations

   40 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03761108 on ClinicalTrials.gov

5. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

   A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Winship Cancer Institute of Emory University, Atlanta, Georgia

   Locations

   29 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT05651932 on ClinicalTrials.gov

6. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

   This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute, Atlanta, Georgia

   Locations

   34 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04910568 on ClinicalTrials.gov

7. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University /ID# 274830, Atlanta, Georgia

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT06892522 on ClinicalTrials.gov

8. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University /ID# 277667, Atlanta, Georgia

   Locations

   49 in total

   Run by

   AbbVie

   See if you can join NCT07095452 on ClinicalTrials.gov

9. CAR T-cell Therapy in Patients With Renal Dysfunction

   This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Caitlin Guzowski, Atlanta, Georgia

   Run by

   Northside Hospital, Inc.

   See if you can join NCT05909059 on ClinicalTrials.gov

10. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Emory University Hospital Midtown, Atlanta, Georgia

    Locations

    93 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07555938 on ClinicalTrials.gov

11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Emory University Hospital, Atlanta, Georgia

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

12. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Winship Cancer Institute of Emory University, Atlanta, Georgia

    Locations

    52 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06297226 on ClinicalTrials.gov

13. Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

    The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University (Data Collection Only), Atlanta, Georgia

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06976476 on ClinicalTrials.gov

14. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

    The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Emory University, Atlanta, Georgia

    Locations

    50 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT05201781 on ClinicalTrials.gov

15. A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

    The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Winship Cancer Institute Emory University, Atlanta, Georgia

    Locations

    16 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT06768489 on ClinicalTrials.gov

16. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Atlanta, Georgia

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07073547 on ClinicalTrials.gov

17. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Emory University, Atlanta, Georgia

    Locations

    150 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07258511 on ClinicalTrials.gov

18. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

    This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory, Atlanta, Georgia

    Locations

    6 in total

    Run by

    Fortvita Biologics (USA)Inc.

    See if you can join NCT07336472 on ClinicalTrials.gov

19. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Emory University, Atlanta, Georgia

    Locations

    173 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07518186 on ClinicalTrials.gov

20. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    Cancer Treatment Centers of America - Atlanta, Atlanta, Georgia

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

21. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

    This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Winship Cancer Institute of Emory University, Atlanta, Georgia

    Locations

    24 in total

    Run by

    Heidelberg Pharma AG

    See if you can join NCT04879043 on ClinicalTrials.gov

22. Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

    This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transpla…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT07101445 on ClinicalTrials.gov

23. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northside Hospital, Atlanta, Georgia

    Locations

    19 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06121843 on ClinicalTrials.gov

24. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Winship Cancer Institute of Emory University, Atlanta, Georgia

    Locations

    42 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05137054 on ClinicalTrials.gov

25. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory Winship Cancer Institute, Atlanta, Georgia

    Locations

    39 in total

    Run by

    CellCentric Ltd.

    See if you can join NCT04068597 on ClinicalTrials.gov